Sign in
CompletedNo phase

Assessment of Cardiorespiratory Fitness Using the PACER in Patients With Juvenile Idiopathic Arthritis and Familial Mediterranean Fever

Key facts

Who runs it
Istanbul University - Cerrahpasa
Where
Türkiye1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
216 people enrolled
Started
25 Dec 2024
Ended
11 May 2025
Type of study
Observational, 3 groups
Treatments tested
  • Usability and Comparison
Record updated
5 June 2025

Who can take part

Age
12 years to 18 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Did not have any chronic disease other than rheumatic disease
  • Diagnosed with rheumatic disease at least 6 months ago
  • Had stable medical treatment
  • Being between the ages of 12 and 18
  • Volunteering to participate in the study

Who cannot take part

  • Have experienced trauma or surgery affecting the musculoskeletal system within the last 6 months
  • Have cognitive impairment
  • Have acute pain for any reason, have visual or hearing problems
  • Not volunteering to participate in the study

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Juvenile Idiopathic Arthritis (JIA) and Familial Mediterranean Fever (FMF) are the most common autoimmune and autoinflammatory rheumatic diseases in childhood. Symptoms such as reduced muscle strength, joint pain, fatigue, and limited activity, which are common in childhood rheumatic diseases, often lead to impaired physical function. Cardiorespiratory fitness, which is an important indicator of physical function, plays a critical role in health-related outcomes in children and adolescents with rheumatic disease. Maximum oxygen consumption (VO2 peak) is considered the fundamental criterion for evaluating cardiorespiratory fitness. The need for extensive equipment and trained personnel, accompanied with the inability to assess large numbers of children at one-time makes the objective assessment of cardiorespiratory fitness in a clinic setting unmanageable. Therefore, there is a need to assess their cardiorespiratory fitness utilizing an easily administered test that has minimal measurement errors in patients with JIA and FMF. The Progressive Aerobic Cardiovascular Endurance Run (PACER) has become a routine cardiorespiratory fitness assessment for predicting VO2peak in children. A review of the literature revealed that no studies have evaluated CRF using PACER in childhood rheumatic diseases. The aim of this study was to compare the Fitnessgram VO2 max values of children and adolescents diagnosed with JIA and FMF with those of their healthy peers and to examine the relationship with body composition.

The 3 groups in the trial

  • Juvenile Idiopathic Arthritis

    Patients diagnosed with JIA followed at the Pediatric Rheumatology Clinic, Department of Pediatrics, Istanbul Faculty of Medicine, will be evaluated.

    Treatment: Usability and Comparison

  • Familial Mediterranean Fever

    Patients diagnosed with FMF followed at the Pediatric Rheumatology Clinic, Department of Pediatrics, Istanbul Faculty of Medicine, will be evaluated.

    Treatment: Usability and Comparison

  • Healthy control

    The outcomes of individuals with rheumatic diseases will be compared with those of healthy controls.

    Treatment: Usability and Comparison

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Assessment of Cardiorespiratory Fitness Using the Progressive Aerobic Cardiovascular Endurance Run in Patients With Juvenile Idiopathic Arthritis and Familial Mediterranean Fever: A Healthy Control Study
Record updated
5 June 2025